📋 Key Information Summary
- Sickle cell disease (SCD) is caused by homozygous or compound-heterozygous haemoglobin variants (HbSS, HbSC, HbS/β-thalassaemia); sickle cell trait (SCT) is the heterozygous carrier state (HbAS) and is almost always benign.
- Confirm diagnosis with haemoglobin electrophoresis or HPLC — do not rely on sickle solubility tests alone; review newborn screening records where available.
- In Australia, SCD predominantly affects people of sub-Saharan African, Middle Eastern, Mediterranean, and South/Southeast Asian descent; prevalence is increasing with immigration.
- Every adult with SCD requires a documented baseline assessment: genotype, crisis frequency, organ complications (renal, pulmonary, cerebrovascular, splenic), vaccination status, and current hydroxyurea use.
- Pneumococcal, meningococcal, Hib, and annual influenza vaccinations are essential due to functional asplenia; follow the ATSI/asplenia immunisation schedule on the National Immunisation Program (NIP).
- Penicillin V prophylaxis (250 mg PO BD) is recommended for patients with functional asplenia or prior splenectomy; continue indefinitely unless contraindicated.
- Folic acid 5 mg PO daily is recommended for all patients with SCD to support erythropoiesis.
- Hydroxyurea (hydroxycarbamide) is first-line disease-modifying therapy — reduces crisis frequency, acute chest syndrome, and transfusion requirements; PBS Authority Required.
- Acute vaso-occlusive crisis requires prompt multimodal analgesia (paracetamol + NSAID ± opioid), IV hydration, and warm compresses; opioids should not be withheld due to misconceptions about addiction.
- Acute chest syndrome is a medical emergency — start broad-spectrum antibiotics, incentive spirometry, simple transfusion, and escalate to exchange transfusion if worsening.
- Stroke symptoms (sudden weakness, speech disturbance, seizure) require immediate emergency department presentation and urgent haematology referral; exchange transfusion is first-line treatment.
- Priapism lasting >4 hours is a urological emergency — encourage oral hydration, analgesia, and urgent aspiration/irrigation by urology if not resolving.
- All acute presentations — pain crisis, ACS, stroke, priapism, splenic sequestration — require urgent hospital admission and haematology consultation.
- Screen regularly for SCD nephropathy (urine ACR, eGFR), pulmonary hypertension (echocardiography), retinopathy, and iron overload if on chronic transfusion.
Introduction & Australian Epidemiology
Sickle cell disease (SCD) is a group of inherited haemoglobinopathies characterised by the production of abnormal haemoglobin S (HbS), leading to red blood cell sickling under deoxygenated conditions. The resulting vaso-occlusion, haemolysis, and endothelial dysfunction cause acute and chronic multi-organ complications. Sickle cell trait (SCT, HbAS) is the heterozygous carrier state and is generally clinically benign, though rare complications can occur under extreme physiological stress.
In Australia, SCD was historically rare but is now a growing clinical concern due to increased migration from endemic regions. The Australian Institute of Health and Welfare (AIHW) and state-based newborn screening programmes have documented rising incidence. Newborn screening for haemoglobinopathies is performed in several states (New South Wales, Victoria, Queensland, Western Australia), enabling early detection. The majority of affected individuals in Australia are of sub-Saharan African descent, followed by those of Middle Eastern, Indian subcontinental, and Mediterranean origin.
Unlike sickle cell disease, sickle cell trait (HbAS) affects an estimated 5–8% of populations from high-prevalence regions living in Australia. While SCT is largely asymptomatic, carriers should receive genetic counselling regarding reproductive risk and be aware of rare complications such as renal medullary carcinoma and splenic infarction at high altitude.
Pathophysiology — Disease vs Trait
Sickle Cell Disease (HbSS, HbSC, HbS/β-thal, HbSD, HbSE)
The fundamental defect is a point mutation in the β-globin gene (GAG→GTG, codon 6), producing haemoglobin S. In the homozygous state (HbSS) or compound heterozygous state (HbSC, HbS/β-thalassaemia), deoxygenated HbS polymerises into rigid fibres that distort the red cell into a sickle shape. Key pathological consequences include:
- Vaso-occlusion: Sickled cells adhere to vascular endothelium, causing microvascular obstruction, ischaemia, and infarction — the basis of painful crises, stroke, and organ damage.
- Chronic haemolysis: Sickled cells have a lifespan of ~17 days (vs ~120 days for normal RBCs), leading to chronic anaemia (Hb 60–90 g/L), reticulocytosis, and elevated unconjugated bilirubin.
- Endothelial dysfunction and chronic inflammation: Free haemoglobin depletes nitric oxide, promoting vasculopathy, pulmonary hypertension, and priapism.
- Functional asplenia: Repeated splenic infarction leads to autosplenectomy by late childhood in HbSS, increasing susceptibility to encapsulated organisms (Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae type b).
Sickle Cell Trait (HbAS)
HbAS individuals have ~40% HbS and ~60% HbA. The presence of HbA prevents significant HbS polymerisation under normal conditions. SCT carriers are generally asymptomatic with a normal lifespan. Rare complications include:
- Renal medullary carcinoma (very rare; screen with urine if haematuria)
- Splenic infarction at high altitude (>3,000 m) or during unpressurised flight
- Hyposthenuria (impaired urinary concentration)
- Rare exertional rhabdomyolysis during extreme physical exertion
Identify SCD vs Trait — Confirm Diagnosis
Accurate identification of the haemoglobin genotype is the cornerstone of SCD management. Clinicians must confirm the specific genotype (HbSS, HbSC, HbS/β-thalassaemia, HbAS) rather than relying on clinical phenotype alone.
Recommended Diagnostic Approach
Interpreting Haemoglobin Electrophoresis / HPLC Results
| Genotype | HbS (%) | HbA (%) | HbF (%) | HbA₂ (%) | Interpretation |
|---|---|---|---|---|---|
| HbAA | 0 | 95–97 | <1 | 2.0–3.5 | Normal |
| HbAS (Trait) | 35–40 | 55–60 | <1 | 2.0–3.5 | Carrier — generally benign |
| HbSS (Disease) | 80–95 | 0 | 2–20 | 2.0–3.5 | Sickle cell disease — most severe |
| HbSC | 45–50 | 0 | 1–5 | Varies | Compound heterozygote — variable severity |
| HbS/β⁰-thal | 80–95 | 0 | 5–20 | 3.5–7.0 | Clinically similar to HbSS |
| HbS/β⁺-thal | 60–80 | 10–30 | 2–10 | 3.5–7.0 | Variable — generally milder than HbSS |
Investigations
Laboratory investigations serve three purposes in SCD: confirming the diagnosis, establishing baseline organ function, and monitoring for disease complications. The following should be performed at diagnosis and at regular intervals thereafter.
Baseline Assessment (Adults)
Every adult with SCD requires a comprehensive baseline assessment at first presentation to primary care or at transition from paediatric services. This assessment should be documented and updated at each clinical encounter.
Essential Baseline Documentation
| Domain | Components to Document | Frequency of Review |
|---|---|---|
| Genotype | Confirmed Hb variant (HbSS, HbSC, HbS/β⁰-thal, HbS/β⁺-thal); date of diagnosis; method of confirmation | Once (confirm with HPLC) |
| Crisis History | Frequency of vaso-occlusive crises per year; typical triggers; usual duration; number of hospital admissions in past 12 months; ICU admissions | Every visit |
| Organ Complications | Stroke / TIA history; acute chest syndrome episodes; splenic status (palpable vs autosplenectomy); renal function (eGFR, ACR); retinopathy; avascular necrosis (hips, shoulders); priapism history; leg ulcers; gallstones | 6–12 monthly |
| Vaccination Status | Pneumococcal (23vPPV & 13vPCV), meningococcal (ACWY & B), Hib, influenza (annual), hepatitis B, COVID-19 | Annual review |
| Hydroxyurea Use | Current dose (mg/kg/day), duration, latest HbF%, side effects, blood count monitoring compliance, pregnancy planning | Every 2–3 months |
| Transfusion History | Lifetime transfusion count, alloantibody status, current on chronic transfusion, iron chelation therapy | Every visit |
| Pain Management Plan | Agreed acute pain management plan; usual effective analgesic regimen; known drug allergies; opioid tolerance status | Every 6–12 months |
| Psychosocial | Employment / education status; psychological wellbeing (PHQ-9); family planning; genetic counselling status; advance care plan | Annual |
Risk Stratification by Genotype
SCD severity varies significantly by genotype. Understanding the patient's genotype guides prognostication, monitoring intensity, and treatment decisions.
Favourable Modifiers
- High HbF (>10%): Associated with fewer crises and improved survival. Hydroxyurea works partly by increasing HbF.
- Co-inherited alpha-thalassaemia: Reduces haemolysis and may lower stroke risk.
- Benin haplotype: Associated with higher baseline HbF compared to Bantu/CAR haplotype.
Primary-Care Maintenance
Primary care plays a central role in the long-term management of adults with SCD. A structured maintenance programme reduces morbidity and prevents life-threatening infections and complications.
Vaccinations (Asplenic / Functionally Asplenic Schedule)
All patients with SCD (particularly HbSS and HbS/β⁰-thal with functional asplenia) require an enhanced vaccination schedule. Follow the Australian Immunisation Handbook asplenia recommendations.
| Vaccine | Schedule | NIP Funded | Notes |
|---|---|---|---|
| Pneumococcal — 13vPCV (Prevenar 13®) | 1 dose (if not previously received); then 23vPPV 2 months later | NIP | For asplenic individuals. Revaccinate 23vPPV every 5 years. |
| Pneumococcal — 23vPPV (Pneumovax 23®) | Every 5 years (lifelong) | NIP | Boosters essential. Document dates. |
| Meningococcal ACWY (Menactra® / Nimenrix®) | Primary dose + booster as per NIP schedule for asplenia | NIP | Boost every 5 years for asplenic patients. |
| Meningococcal B (Bexsero®) | 2 doses, 4–8 weeks apart | NIP | Funded for asplenic individuals <25 years; discuss with GP for older adults. |
| Haemophilus influenzae type b (Hib) | 1 dose if not previously vaccinated | NIP | For asplenic individuals. Single booster dose. |
| Influenza (annual) | Every year before winter | NIP | All SCD patients — high priority group. |
| COVID-19 | As per current ATAGI recommendations for immunocompromised / at-risk | NIP | SCD patients are priority group. |
Antibiotic Prophylaxis
Folate Supplementation
Infection Education
- Educate patients to present urgently (within 1 hour) for fever ≥38°C — functional asplenia places them at risk of rapidly fatal sepsis from encapsulated organisms.
- Advise empirical self-treatment with oral amoxicillin 1 g PO stat (if previously dispensed as standby) while arranging emergency department presentation.
- Counsel on hygiene measures, dental care, and avoiding contact with individuals with respiratory infections.
- Recommend Medicalert® bracelet or card stating diagnosis and functional asplenia status.
- Provide an individualised written fever and crisis action plan.
Empirical Therapy — Acute Pain Management
Vaso-occlusive crisis (VOC) is the most common acute presentation of SCD, accounting for >90% of emergency department visits. Pain should be assessed promptly using a validated pain scale, and treatment initiated within 30 minutes of presentation. Opioids should not be withheld or under-dosed due to misconceptions about addiction — undertreated pain worsens the crisis.
Acute VOC Analgesia Ladder
Supportive Measures During VOC
- IV fluids: Normal saline 0.9% — avoid overhydration (risk of ACS). Aim for euvolaemia; 1–1.5 mL/kg/hr unless dehydrated.
- Warm compresses to affected areas; warm environment.
- Incentive spirometry: 10 breaths every 2 hours while awake — prevents microatelectasis and ACS.
- Antiemetics: Ondansetron 4 mg IV/PO PRN for opioid-induced nausea.
- Thromboprophylaxis: LMWH (enoxaparin 40 mg SC daily) unless contraindicated — SCD patients are prothrombotic during hospitalisation.
Directed Disease-Modifying Therapy
Disease-modifying therapies aim to reduce the frequency and severity of SCD complications, decrease transfusion requirements, and improve quality of life. Hydroxyurea remains the cornerstone of SCD disease modification.
Chronic Transfusion Programme
Chronic simple or exchange transfusion is indicated for:
- Primary stroke prevention: Children/adolescents with abnormal transcranial Doppler (TCD); continued into adulthood if started in childhood.
- Secondary stroke prevention: After first stroke — lifelong chronic transfusion to maintain HbS <30%.
- Recurrent acute chest syndrome not controlled by hydroxyurea.
- Severe symptomatic anaemia (Hb <50 g/L with symptoms) unresponsive to other measures.
Patients on chronic transfusion require iron chelation to prevent transfusional iron overload:
Curative Therapies
Acute Issues & Referral
Certain acute presentations in SCD constitute medical emergencies and require immediate hospital admission and specialist haematology input. Primary care clinicians must recognise these presentations and facilitate urgent transfer.
Emergency Presentations Requiring Immediate Referral
| Acute Presentation | Key Features | Immediate Actions | Definitive Management |
|---|---|---|---|
| Vaso-Occlusive Crisis (VOC) | Severe pain — typically bones (long bones, back, chest, abdomen); may be triggered by dehydration, cold, infection, stress, menses | Multimodal analgesia within 30 min; IV fluids; incentive spirometry; FBC, blood cultures if febrile | Hospital admission if not controlled within 2 hours of ED treatment; haematology consult |
| Acute Chest Syndrome (ACS) | New pulmonary infiltrate + fever >38.5°C, chest pain, hypoxia, cough, or dyspnoea. May be triggered by infection, fat embolism, or atelectasis. High mortality risk. | O₂ to keep SpO₂ >95%; broad-spectrum antibiotics (ceftriaxone + azithromycin); incentive spirometry; simple transfusion if Hb <90 g/L or SpO₂ <92% | ICU admission; exchange transfusion if worsening (target HbS <30%); haematology and ICU co-management |
| Stroke | Sudden-onset focal neurological deficit (hemiparesis, aphasia, visual field defect); seizure; altered consciousness. Both large-vessel (vaso-occlusive) and small-vessel (haemorrhagic) types occur. | Activate stroke pathway; urgent CT head (exclude haemorrhage); immediate haematology referral | Exchange transfusion (target HbS <30%, Hb ~100 g/L); MRI/MRA; long-term chronic transfusion for secondary prevention |
| Priapism | Painful, sustained erection >4 hours. Low-flow (ischaemic) type is most common in SCD. Urological emergency — risk of erectile dysfunction if not treated promptly. | Oral hydration; analgesia; attempt voiding; penile aspiration with or without irrigation (urology) | Urology referral <4 hours; phenylephrine injection into corpora cavernosa; surgical shunt if refractory; haematology input |
| Splenic Sequestration | Rapid splenic enlargement with acute drop in Hb (>20 g/L fall from baseline); abdominal pain, left upper quadrant fullness. Can be fatal if unrecognised. | FBC, cross-match; IV access; fluid resuscitation if haemodynamically unstable | Simple transfusion; splenectomy may be considered for recurrent episodes; haematology admission |
| Aplastic Crisis | Reticulocytopenia with worsening anaemia. Often triggered by parvovirus B19 infection. Self-limiting (7–10 days) but may require transfusion. | FBC + reticulocyte count; parvovirus B19 serology/PCR; cross-match | Simple transfusion if Hb <50 g/L or symptomatic; isolation precautions (parvovirus is contagious) |
| Fever / Sepsis | Temperature ≥38°C in a functionally asplenic patient. Treat as sepsis until proven otherwise — S. pneumoniae, N. meningitidis, Salmonella spp., E. coli. | Blood cultures; FBC, CRP, lactate; empirical IV antibiotics within 1 hour: ceftriaxone 2 g IV stat | Hospital admission; tailor antibiotics to culture results; consider adding vancomycin if MRSA risk |
Emergency Antibiotics for Febrile SCD
When to Refer to Haematology
- Urgent referral (same day): Any acute SCD complication (VOC not responding to standard analgesia, ACS, stroke, priapism, sequestration, aplastic crisis, fever)
- Elective referral: Newly diagnosed SCD; annual comprehensive review; initiation or titration of hydroxyurea; chronic transfusion programme; pre-pregnancy planning; HSCT consideration
- Not routinely referred: Sickle cell trait (unless reproductive counselling or rare complication)
Monitoring
Regular monitoring enables early detection of organ complications, optimisation of disease-modifying therapy, and prevention of avoidable morbidity.
Routine Monitoring Schedule
| Investigation | Frequency | Purpose / Target |
|---|---|---|
| FBC with reticulocyte count | Every 2–3 months (hydroxyurea); every 6 months (stable, no HU) | Monitor Hb, WCC, platelets; detect aplastic crisis; assess hydroxyurea response |
| Haemoglobin electrophoresis / HPLC | Annually (or after dose change of HU) | Track HbF% (target >10–20% on hydroxyurea) |
| Renal function (eGFR, urine ACR) | Every 6–12 months | Detect SCD nephropathy; early proteinuria warrants ACE inhibitor |
| LFTs + bilirubin | Every 6–12 months | Hepatic sequestration; cholelithiasis; iron overload |
| Serum ferritin + transferrin saturation | Every 3–6 months (transfused); annually (non-transfused) | Iron overload surveillance; target ferritin <500 µg/L in transfused patients |
| LDH + haptoglobin | Every 6–12 months | Baseline haemolysis markers; rising LDH may indicate complication |
| Vitamin D, B12, folate | Annually | Bone health; erythropoietic support |
| Echocardiography | Every 2–3 years or if symptoms | Screen for pulmonary hypertension (TRV >2.5 m/s) |
| Ophthalmology (dilated fundoscopy) | Annually (especially HbSC) | Proliferative sickle retinopathy screening |
| Transcranial Doppler / MRI brain | As directed by haematology (annually in high-risk patients) | Silent cerebral infarcts; stroke risk assessment |
Hydroxyurea Monitoring Protocol
Special Populations
Pregnancy
SCD in pregnancy is high-risk. Increased frequency of VOC, ACS, pre-eclampsia, preterm delivery, fetal growth restriction, and maternal mortality.
Hydroxyurea is teratogenic — must be discontinued at least 3 months before conception (both men and women). Discuss with haematology and obstetrics early.
Folic acid dose: Increase to 5 mg daily (standard SCD dose; adequate for pregnancy).
Thromboprophylaxis: LMWH from first trimester through 6 weeks postpartum (high VTE risk).
Joint obstetric–haematology care at a tertiary centre is essential. Refer early in pregnancy.
Key drugs: Enoxaparin 40 mg SC daily; folic acid 5 mg PO daily; paracetamol for pain (avoid NSAIDs after 30 weeks).
Note: Contraception counselling should be provided to all women of reproductive age on hydroxyurea — LARC (IUD, implant) preferred.
Elderly (≥65 years)
With improved survival, more patients are living into their 60s and beyond. Cumulative organ damage is the primary concern.
Increased risk of renal failure (SCD nephropathy), pulmonary hypertension, heart failure, and iron overload.
Analgesic management requires caution — lower opioid doses, monitor renal function, consider gabapentin/pregabalin for chronic pain.
Polypharmacy risk — regular medication review. Avoid nephrotoxins where possible.
Note: Fall prevention strategies are important — avascular necrosis of hips increases fall risk.
Renal Impairment
SCD nephropathy affects up to 30% of adults — presents as hyperfiltration → microalbuminuria → proteinuria → CKD → ESKD.
ACE inhibitors (ramipril 2.5–10 mg daily) are first-line for microalbuminuria — reduces proteinuria progression.
Hydroxyurea: Reduce dose if eGFR <30 mL/min. Monitor FBC more frequently.
NSAIDs: Avoid or use with extreme caution — exacerbate renal impairment in SCD.
Renal replacement therapy outcomes in SCD patients on dialysis are comparable to non-SCD CKD patients with appropriate management.
Note: Refer to nephrology when eGFR <30 mL/min or proteinuria progressing despite ACE inhibitor.
Hepatic Complications
Hepatic sequestration: Rapid hepatomegaly with falling Hb and rising bilirubin — may be life-threatening. Requires urgent transfusion.
Cholelithiasis: Pigment gallstones are nearly universal in adults with SCD due to chronic haemolysis. Cholecystectomy for symptomatic disease.
Iron overload: Monitor ferritin and liver iron concentration (MRI) in chronically transfused patients. Chelation with deferasirox.
Avoid hepatotoxic drugs where possible; monitor LFTs regularly.
Note: Transfusion-transmitted hepatitis screening is mandatory (Hep B, Hep C, HIV).
Immunocompromised / Functional Asplenia
All patients with HbSS and HbS/β⁰-thal have functional asplenia by age 5. HbSC patients may retain splenic function longer but still have impaired splenic filtration.
Increased susceptibility to encapsulated organisms: S. pneumoniae, N. meningitidis, H. influenzae type b, Salmonella spp.
Ensure enhanced vaccination schedule (see Primary-Care Maintenance) and penicillin prophylaxis.
Howell-Jolly bodies on blood film confirm functional asplenia.
Note: Malaria prophylaxis and avoidance are critical for SCD patients travelling to endemic regions — seek specialist travel medicine advice.
📚 References
- 1. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376(9757):2018–2031.
- 2. National Heart, Lung, and Blood Institute (NHLBI). Evidence-Based Management of Sickle Cell Disease: Expert Panel Report. US Department of Health and Human Services; 2014.
- 3. Howard J, Hart N, Roberts-Harewood M, et al. Guideline on the management of acute chest syndrome in sickle cell disease. Br J Haematol. 2015;169(4):492–505.
- 4. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390(10091):311–323.
- 5. Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017;376(16):1561–1573.
- 6. Australian Institute of Health and Welfare (AIHW). Blood disorders in Australia 2024. AIHW, Canberra; 2024.
- 7. Estcourt LJ, Fortin PM, Hopewell S, Trivella M, Wang WC. Blood transfusion for treating acute chest syndrome in people with sickle cell disease. Cochrane Database Syst Rev. 2017;1(1):CD007843.
- 8. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health, Canberra; 2024. [Online: immunisationhandbook.health.gov.au].
- 9. Rankine-Mullings AE, Nevitt SJ. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database Syst Rev. 2022;9(9):CD002202.
- 10. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med. 2000;342(25):1855–1865.
- 11. Brandow AM, Panepinto JA. Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities. Expert Rev Hematol. 2020;13(5):475–484.
- 12. Royal Australian College of General Practitioners (RACGP). Management of chronic conditions in Aboriginal and Torres Strait Islander populations. RACGP, Melbourne; 2023.
- 13. National Pathology Accreditation Advisory Council (NPAAC). Standards for laboratories reporting human molecular genetic tests. Australian Government Department of Health; 2019.
- 14. Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429–439.
- 15. Vichinsky EP, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019;381(6):509–519.